WallStreetZenWallStreetZen

NASDAQ: GLUE
Monte Rosa Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for GLUE

Based on 2 analysts offering 12 month price targets for Monte Rosa Therapeutics Inc.
Min Forecast
$11.00+56.25%
Avg Forecast
$11.00+56.25%
Max Forecast
$11.00+56.25%

Should I buy or sell GLUE stock?

Based on 2 analysts offering ratings for Monte Rosa Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GLUE stock forecasts and price targets.

GLUE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-15
lockedlocked$00.00+00.00%2023-10-19

1 of 1

Forecast return on equity

Is GLUE forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
37.5%

Forecast return on assets

Is GLUE forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

GLUE revenue forecast

What is GLUE's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$17.2M
Avg 2 year Forecast
$17.2M
Avg 3 year Forecast
$15.6M

GLUE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GLUE$7.04$11.00+56.25%Strong Buy
MESO$3.49N/AN/A
ENTA$16.53$19.60+18.57%Hold
ADCT$4.20$8.50+102.38%Buy
NAUT$2.77N/AN/A

Monte Rosa Therapeutics Stock Forecast FAQ

Is Monte Rosa Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: GLUE) stock is to Strong Buy GLUE stock.

Out of 2 analysts, 1 (50%) are recommending GLUE as a Strong Buy, 1 (50%) are recommending GLUE as a Buy, 0 (0%) are recommending GLUE as a Hold, 0 (0%) are recommending GLUE as a Sell, and 0 (0%) are recommending GLUE as a Strong Sell.

If you're new to stock investing, here's how to buy Monte Rosa Therapeutics stock.

What is GLUE's revenue growth forecast for 2024-2026?

(NASDAQ: GLUE) Monte Rosa Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.

Monte Rosa Therapeutics's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast GLUE's revenue for 2024 to be $863,653,137, with the lowest GLUE revenue forecast at $836,068,397, and the highest GLUE revenue forecast at $891,237,877. On average, 2 Wall Street analysts forecast GLUE's revenue for 2025 to be $863,653,137, with the lowest GLUE revenue forecast at $836,068,397, and the highest GLUE revenue forecast at $891,237,877.

In 2026, GLUE is forecast to generate $780,648,146 in revenue, with the lowest revenue forecast at $725,227,896 and the highest revenue forecast at $836,068,397.

What is GLUE's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: GLUE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is GLUE's Price Target?

According to 2 Wall Street analysts that have issued a 1 year GLUE price target, the average GLUE price target is $11.00, with the highest GLUE stock price forecast at $11.00 and the lowest GLUE stock price forecast at $11.00.

On average, Wall Street analysts predict that Monte Rosa Therapeutics's share price could reach $11.00 by Feb 15, 2025. The average Monte Rosa Therapeutics stock price prediction forecasts a potential upside of 56.25% from the current GLUE share price of $7.04.

What is GLUE's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: GLUE) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.